Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market 2019 by Company, Regions, Type and Application, Forecast to 2024
June 2019
136
About the Report
About the Report
Scope of the Report:
The global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Non-Peptide Drugs of Angiotensin II Receptor Antagonist.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Non-Peptide Drugs of Angiotensin II Receptor Antagonist market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-Peptide Drugs of Angiotensin II Receptor Antagonist market by product type and applications/end industries.
Market Segment by Companies, this report covers
Pfizer
Novartis
Merck
AstraZeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Sun Pharmaceutical
Mylan
Alembic Pharmaceuticals
Lupin
Aurobindo Pharma
Amneal Pharmaceuticals
Boehringer Ingelheim
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Valsartan
Irbesartan
Candesartan Cilexetil
Eprosartan
Irbesartan
Telmisartan
losartan
Olmesartan Medoxomil
Allisartan isoproxil
Market Segment by Applications, can be divided into
High Blood Pressure
Congestive Heart Failure
Left Ventricular Hypertrophy
Atherosclerosis
Other
Products
Companies
Pfizer
Novartis
Merck
AstraZeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Sun Pharmaceutical
Mylan
Alembic Pharmaceuticals
Lupin
Aurobindo Pharma
Amneal Pharmaceuticals
Boehringer Ingelheim
Table of Contents
Table of Contents
Table of Contents
1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Overview
1.1 Product Overview and Scope of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
1.2 Classification of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Types
1.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Comparison by Types (2019-2024)
1.2.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Types in 2018
1.2.3 Valsartan
1.2.4 Irbesartan
1.2.5 Candesartan Cilexetil
1.2.6 Eprosartan
1.2.7 Irbesartan
1.2.8 Telmisartan
1.2.9 losartan
1.2.10 Olmesartan Medoxomil
1.2.11 Allisartan isoproxil
1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Application
1.3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 High Blood Pressure
1.3.3 Congestive Heart Failure
1.3.4 Left Ventricular Hypertrophy
1.3.5 Atherosclerosis
1.3.6 Other
1.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Regions
1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
1.5 Global Market Size of Non-Peptide Drugs of Angiotensin II Receptor Antagonist (2014-2024)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.3 Merck
2.3.1 Business Overview
2.3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.4 AstraZeneca
2.4.1 Business Overview
2.4.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.5 Jhonson and Johnson
2.5.1 Business Overview
2.5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.6 Eli Lilly
2.6.1 Business Overview
2.6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.7 Sanofi
2.7.1 Business Overview
2.7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.8 Bristol-Myers Squibb
2.8.1 Business Overview
2.8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.9 Bayer
2.9.1 Business Overview
2.9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.10 GSK
2.10.1 Business Overview
2.10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.11 Teva Pharmaceutical
2.11.1 Business Overview
2.11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.12 Shenzhen Salubris Pharmaceuticals
2.12.1 Business Overview
2.12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.13 Sun Pharmaceutical
2.13.1 Business Overview
2.13.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.14 Mylan
2.14.1 Business Overview
2.14.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.15 Alembic Pharmaceuticals
2.15.1 Business Overview
2.15.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.16 Lupin
2.16.1 Business Overview
2.16.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.17 Aurobindo Pharma
2.17.1 Business Overview
2.17.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.18 Amneal Pharmaceuticals
2.18.1 Business Overview
2.18.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
2.19 Boehringer Ingelheim
2.19.1 Business Overview
2.19.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Competition, by Players
3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share
3.2.2 Top 10 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share
3.3 Market Competition Trend
4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions
4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Regions
4.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
4.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
4.5 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
5 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries
5.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
5.2 USA Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
5.3 Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
5.4 Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
6 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries
6.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
6.2 Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
6.3 UK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
6.4 France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
6.5 Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
6.6 Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries
7.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
7.2 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
7.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
7.4 Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
7.5 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
8 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries
8.1 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
8.2 Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
8.3 Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
8.4 Colombia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Countries
9.1 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
9.2 Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
9.3 UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
9.4 Egypt Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
9.5 Nigeria Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
9.6 South Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
10 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segment by Type
10.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Type (2014-2019)
10.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Type (2019-2024)
10.3 Valsartan Revenue Growth Rate (2014-2024)
10.4 Irbesartan Revenue Growth Rate (2014-2024)
10.5 Candesartan Cilexetil Revenue Growth Rate (2014-2024)
10.6 Eprosartan Revenue Growth Rate (2014-2024)
10.7 Irbesartan Revenue Growth Rate (2014-2024)
10.8 Telmisartan Revenue Growth Rate (2014-2024)
10.9 losartan Revenue Growth Rate (2014-2024)
10.10 Olmesartan Medoxomil Revenue Growth Rate (2014-2024)
10.11 Allisartan isoproxil Revenue Growth Rate (2014-2024)
11 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segment by Application
11.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2014-2019)
11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Application (2019-2024)
11.3 High Blood Pressure Revenue Growth (2014-2019)
11.4 Congestive Heart Failure Revenue Growth (2014-2019)
11.5 Left Ventricular Hypertrophy Revenue Growth (2014-2019)
11.6 Atherosclerosis Revenue Growth (2014-2019)
11.7 Other Revenue Growth (2014-2019)
12 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast (2019-2024)
12.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast (2019-2024)
12.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Regions (2019-2024)
12.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
12.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
12.6 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Table
List of Tables and Figures
Figure Non-Peptide Drugs of Angiotensin II Receptor Antagonist Picture
Table Product Specifications of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist and Revenue (Million USD) Market Split by Product Type
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Types in 2018
Figure Valsartan Picture
Figure Irbesartan Picture
Figure Candesartan Cilexetil Picture
Figure Eprosartan Picture
Figure Irbesartan Picture
Figure Telmisartan Picture
Figure losartan Picture
Figure Olmesartan Medoxomil Picture
Figure Allisartan isoproxil Picture
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Application (2014-2024)
Figure Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Applications in 2018
Figure High Blood Pressure Picture
Figure Congestive Heart Failure Picture
Figure Left Ventricular Hypertrophy Picture
Figure Atherosclerosis Picture
Figure Other Picture
Table Global Market Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (2014-2024)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Novartis Basic Information, Manufacturing Base and Competitors
Table Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table AstraZeneca Basic Information, Manufacturing Base and Competitors
Table AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Jhonson and Johnson Basic Information, Manufacturing Base and Competitors
Table Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Eli Lilly Basic Information, Manufacturing Base and Competitors
Table Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Bayer Basic Information, Manufacturing Base and Competitors
Table Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table GSK Basic Information, Manufacturing Base and Competitors
Table GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Shenzhen Salubris Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Mylan Basic Information, Manufacturing Base and Competitors
Table Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Alembic Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Lupin Basic Information, Manufacturing Base and Competitors
Table Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Amneal Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
Table Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Players (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players in 2017
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players in 2018
Figure Global Top 5 Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share in 2018
Figure Global Top 10 Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share in 2018
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Regions (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Regions (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Regions (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Regions in 2018
Figure North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Table North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
Table North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries in 2018
Figure USA Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Table Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Countries (2014-2019)
Figure Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries in 2018
Figure Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure UK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries in 2018
Figure China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Table South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
Table South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries in 2018
Figure Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Colombia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Countries in 2018
Figure Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Egypt Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure Nigeria Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Figure South Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) by Type (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Type (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Type (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Type in 2018
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Forecast by Type (2019-2024)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Forecast by Type (2019-2024)
Figure Global Valsartan Revenue Growth Rate (2014-2019)
Figure Global Irbesartan Revenue Growth Rate (2014-2019)
Figure Global Candesartan Cilexetil Revenue Growth Rate (2014-2019)
Figure Global Eprosartan Revenue Growth Rate (2014-2019)
Figure Global Irbesartan Revenue Growth Rate (2014-2019)
Figure Global Telmisartan Revenue Growth Rate (2014-2019)
Figure Global losartan Revenue Growth Rate (2014-2019)
Figure Global Olmesartan Medoxomil Revenue Growth Rate (2014-2019)
Figure Global Allisartan isoproxil Revenue Growth Rate (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2014-2019)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Application (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Application (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Application in 2018
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Forecast by Application (2019-2024)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Forecast by Application (2019-2024)
Figure Global High Blood Pressure Revenue Growth Rate (2014-2019)
Figure Global Congestive Heart Failure Revenue Growth Rate (2014-2019)
Figure Global Left Ventricular Hypertrophy Revenue Growth Rate (2014-2019)
Figure Global Atherosclerosis Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
Figure Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
Figure South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.